Skip to content

EBIT at other companies

Septerna, Inc. logo
Septerna, Inc.SEPN
-$13.3M+48.7%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$53.42M-148%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-$57.99M-66.3%
Zymeworks logo
ZymeworksZYME
-$47.12M-84.0%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$92.5M-47.1%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Calculated from MAZE’s reported figures.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's EBIT?
MAZE (MAZE) reported EBIT of -$26.55M in Q1 2026.
How has MAZE's EBIT changed year-over-year?
MAZE's EBIT increased by 25.0% year-over-year, from -$35.4M to -$26.55M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.